Navigation Links
Arena Pharmaceuticals Submits New Drug Application to FDA for Lorcaserin for Weight Management
Date:12/22/2009

SAN DIEGO, Dec. 22, 2009 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that it has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for lorcaserin, Arena's internally discovered and developed drug candidate for weight management, including weight loss and maintenance of weight loss. The submission is based on an extensive data package from lorcaserin's clinical development program that includes 18 clinical trials totaling 8,576 patients.

William R. Shanahan, M.D., Arena's Vice President and Chief Medical Officer, stated, "Physicians need new, better-tolerated approaches to improve the treatment of patients who are obese or significantly overweight. Based on the robust data package we submitted to the FDA, lorcaserin has the potential to meet this need, offering patients the opportunity to achieve sustainable weight loss in a well-tolerated manner and improve their cardiometabolic health and quality of life."

The pivotal Phase 3 clinical trial program, BLOOM (Behavioral modification and Lorcaserin for Overweight and Obesity Management) and BLOSSOM (Behavioral modification and LOrcaserin Second Study for Obesity Management), evaluated nearly 7,200 patients treated for up to two years and showed that lorcaserin consistently produced significant weight loss with excellent safety and tolerability.

"Today's NDA submission is an important milestone towards realizing lorcaserin's significant commercial potential, and we are excited by the possibility of bringing lorcaserin to patients who need help in managing their weight," said Jack Lief, Arena's President and Chief Executive Officer. "Physician feedback suggests that, if approved, lorcaserin's combination of efficacy, safety and tolerability will position the drug candidate a
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Arena Pharmaceuticals to Present at Four Upcoming Investor Conferences
2. Arena Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of APD125 for the Treatment of Insomnia
3. Arena Pharmaceuticals Announces APD668 Initial Clinical Study Results Suggest Glucose-Dependent Insulinotropic Receptors May Improve Glucose Control in Patients With Type 2 Diabetes
4. Arena Pharmaceuticals Announces Positive Phase 1a Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis and Initiates Phase 1b Clinical Trial
5. Arena Pharmaceuticals Initiates Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
6. Arena Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of Drug Candidate Under Partnership with Taisho Pharmaceutical Co., Ltd.
7. Arena Pharmaceuticals Presented Positive Phase 2a Clinical Trial Results of APD125 for the Treatment of Insomnia at 22nd Annual Meeting of the Associated Professional Sleep Societies
8. Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis
9. Critical Pharmaceuticals Enter Sustained Release hGH Arena
10. Arena Pharmaceuticals Announces Preliminary Results of Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
11. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Type 2 Diabetes Drug Candidate in Partnership with Ortho-McNeil-Janssen Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... , Sept. 15, 2014 /PRNewswire-iReach/ -- MedicOne Medical ... transport services, has been selected by Inc. Magazine ... in America. Photo - ... 500|5000 list identifies successful, privately-held companies with the ... Medical Response, one of only two ambulance companies ...
(Date:9/15/2014)... , Sept. 15, 2014  Catalist-listed QT Vascular Ltd. ... a developer and manufacturer of minimally invasive medical devices ... announce that the Group has enrolled the first European ... . Multiple patients have already been enrolled in ... Auckland City Hospital, in Auckland, New Zealand ...
(Date:9/15/2014)... NEW YORK , Sept. 15, 2014 /PRNewswire/ ... together under one roof Saturday to learn, interact ... treatments at New York City,s first Lupus Trials Fair ... (LRI) and the S.L.E. Lupus Foundation . ... NYC,s leading institutions -- sharing experiences, ideas and ...
Breaking Medicine Technology:MedicOne Medical Response Named to 2014 Inc. 5000 Fastest Growing Companies List 2MedicOne Medical Response Named to 2014 Inc. 5000 Fastest Growing Companies List 3First European Patients Enrolled in QT Vascular's ENDURE Trial 2First European Patients Enrolled in QT Vascular's ENDURE Trial 3First European Patients Enrolled in QT Vascular's ENDURE Trial 4First European Patients Enrolled in QT Vascular's ENDURE Trial 5Lupus Research Institute Launches NYC's First Lupus Trials Fair 2Lupus Research Institute Launches NYC's First Lupus Trials Fair 3
(Date:9/16/2014)... Syracuse, NY (PRWEB) September 16, 2014 ... HearStrong Champion Danielle Strassle at the 2014 Buffalo Bills ... in Buffalo, NY. , Bills legend and NFL ... , assisted the foundation in honoring Strassle for her ... and professional goals and inspire others in her community ...
(Date:9/16/2014)... Online retailer Kettlebell Kings has announced that ... kettlebell purchases in their online store. The company wants ... with this effective workout method that is quickly gaining ... carries a variety of kettlebell brands as well as ... , “We’ve seen for ourselves how effective kettlebells ...
(Date:9/16/2014)... Yellow Spings, OH (PRWEB) September 16, 2014 ... the Master of Arts in Clinical Mental Health ... offering joins a growing list of programs offered through ... the spring semester starting January 2015. , "Antioch University ... a strong reputation in the field and a track ...
(Date:9/16/2014)... Issaquah, WA (PRWEB) September 16, 2014 ... of medical equipment and supplies and a veteran-owned ... lines for medical professionals-- Jant Pharmacal Corporation, Nipro ... is committed to providing its customers the best, ... serve its current customers, and in an effort ...
(Date:9/16/2014)... The Living Ethics lecture series returns ... on what it means to live in an ethically ... and thought-provoking topics. , “The Museum’s job is to ... at their world differently. The Living Ethics series’ ... truly enlightening dialogue,” says Richard Conti, Chief Wonder Officer, ...
Breaking Medicine News(10 mins):Health News:The HearStrong Foundation and the Buffalo Bills Alumni Foundation Celebrated HearStrong Champion During 2014 Alumni Weekend 2Health News:Join the Kettlebell Movement - Kettlebell Kings Announces $0 Shipping on all Orders 2Health News:Antioch University Launches Online Master’s Degree Program in Clinical Mental Health Counseling 2Health News:Expanding Community Vision at the Science Museum of Virginia 2
... A recent study finds that, TACE inhibitors currently developed ... control proliferation of tumor cells. TACE is// strongly present ... to current therapies. ,TACE (tumor necrosis factor-alpha-converting ... pair of ligands, called Amphiregulin and TGF-alpha, from the ...
... states have registered a leap in the number of dengue ... authorities fearing that the mosquito-borne// disease could further spread due ... ,The north-eastern state of Kelantan registered the highest jump, from ... cases in the first week of January. ...
... and Drug Administration has given the go-ahead to the ... otherwise called fat loss,// occurring in patients with AIDS ... assist in the manufacture of collagen. ,To ... on a study of 100 HIV patients suffering facial ...
... worried about the lack of natural B vitamin "folate" in ... has linked the inadequacy of this vitamin to birth defects ... to breads and cereals being supplemented with folic acid. This ... nation-wide study, undertaken between 1999 and 2004 showed that more ...
... by Jane Carlton, Ph.D., a parasite specialist and an associate ... University// School of Medicine, have successfully decoded the genome of ... STD that usually affects both men and women. ... of the journal Science. ,Moreover, this 4-year ...
... to a British Muslim scholar a special and specific health ... of Edinburgh University// believes that this could hold the key ... ,While sharing his thoughts in the British Medical Journal, professor ... realize this need and bring about a change in the ...
Cached Medicine News:Health News:A New Strategy to Control Breast Cancer 2Health News:Mosquito-borne Dengue Disease on the Rise in Five Malaysian States 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: